 The Deal Pipeline | Abbott Pays Action $110M for Global Rights to Phase II-Stage Acute Kidney ... Genetic Engineering News Abbott is paying Denmark's Action Pharma $110 million for global rights to develop and commercialize the latter's AP214, a Phase II-stage alpha-MSH peptide derivative currently in development for preventing acute kidney injury associated with major ... Abbott to Acquire Action Pharma's Investigational Compound, AP214, in Phase 2b ... Zealand Pharma Signs Licensing Agreement With Abbott for the Further Clinical ... Abbott buys potential kidney treatment for $110M |
